Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Axovant Sciences Ltd (AXGT)

Axovant Sciences Ltd (AXGT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 125,198
  • Shares Outstanding, K 36,823
  • Annual Sales, $ 0 K
  • Annual Income, $ -129,070 K
  • 60-Month Beta 1.55
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 15.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.59
  • Number of Estimates 5
  • High Estimate -0.38
  • Low Estimate -0.74
  • Prior Year -0.45
  • Growth Rate Est. (year over year) -31.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.92 +15.75%
on 05/08/20
3.65 -7.40%
on 05/18/20
+0.19 (+5.96%)
since 05/01/20
3-Month
1.41 +139.72%
on 03/18/20
3.94 -14.21%
on 04/17/20
+0.56 (+19.86%)
since 03/03/20
52-Week
1.41 +139.72%
on 03/18/20
8.52 -60.33%
on 06/21/19
-3.43 (-50.37%)
since 06/03/19

Most Recent Stories

More News
Axovant (AXGT) Moves to Strong Buy: Rationale Behind the Upgrade

Axovant (AXGT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AXGT : 3.40 (-0.88%)
Will Ventilator Sales Drive Medtronic's (MDT) Q4 Earnings?

Medtronic (MDT) might have registered lower demand for its emergency procedures in Q4 with patients trying to avoid any non-COVID-19 emergency treatment.

MDT : 97.37 (+0.12%)
SMMT : 3.54 (-5.60%)
CGC : 16.81 (+4.15%)
AXGT : 3.40 (-0.88%)
CytoDyn (CYDY) to Report Q4 Earnings: What's in the Cards?

On CytoDyn's (CYDY) upcoming earnings call, investor focus will be on the updates related to its CCR5 antagonist candidate, leronlimab, which is being developed for multiple therapeutic indications.

BLFS : 16.17 (+0.68%)
CYDY : 2.9300 (-1.35%)
SMMT : 3.54 (-5.60%)
AXGT : 3.40 (-0.88%)
All You Need to Know About Axovant (AXGT) Rating Upgrade to Buy

Axovant (AXGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AXGT : 3.40 (-0.88%)
Axovant: Fiscal 3Q Earnings Snapshot

LONDON (AP) _ Axovant Sciences Ltd. (AXGT) on Monday reported a loss of $14 million in its fiscal third quarter.

AXGT : 3.40 (-0.88%)
What Makes Axovant (AXGT) a New Buy Stock

Axovant (AXGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AXGT : 3.40 (-0.88%)
Axovant's GM1 Gangliosidosis Candidate Gets Orphan Drug Tag

The FDA grants Orphan Drug status to Axovant's (AXGT) gene therapy candidate, AXO-AAV-GM1, being developed for the treatment of GM1 gangliosidosis. Shares decline despite the positive news.

IDRA : 2.04 (-3.77%)
NTLA : 22.52 (+11.15%)
ANIK : 33.15 (-4.85%)
AXGT : 3.40 (-0.88%)
Axovant Gene Therapies Enters Oversold Territory

Axovant Gene Therapies has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

AXGT : 3.40 (-0.88%)
Axovant (AXGT) Moves to Strong Buy: Rationale Behind the Upgrade

Axovant (AXGT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AXGT : 3.40 (-0.88%)
Axovant (AXGT) Upgraded to Buy: Here's What You Should Know

Axovant (AXGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AXGT : 3.40 (-0.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade AXGT with:

Business Summary

Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer's disease...

See More

Key Turning Points

2nd Resistance Point 3.54
1st Resistance Point 3.47
Last Price 3.40
1st Support Level 3.30
2nd Support Level 3.20

See More

52-Week High 8.52
Fibonacci 61.8% 5.80
Fibonacci 50% 4.97
Fibonacci 38.2% 4.13
Last Price 3.40
52-Week Low 1.41

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar